Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
evidence of the efficacy of bevacizumab in patients with HHT.Both cases also show that symptoms and transfusion requirements improve with this therapy, without an appreciable change in arteriovenous malformations.Like Oosting et al., we found no difference in the size of our patient's pulmonary arteriovenous malformations on CT before and after bevacizumab.Their experience demonstrates the long-term safety and tolerability of bevacizumab in such patients.Our patient continues to report symptomatic benefit more than a year after completing therapy, and he has required only one intravenous infusion of iron during this time.His hemoglobin levels have remained stable at 14 to 15 g per deciliter.The cost of our patient's regimen (a total of 30 mg per kilogram over four cycles) would be approximately $12,000 today.The costs of continuing the drug in the long term, especially without a Food and Drug Administration-approved indication, would be prohibitive.Our case shows that intermittent dosing allows for long-term, symptomatic improvement and stability of pulmonary arteriovenous malformations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this patient, RDN resulted in a progressive decrease in blood pressure from 161/107 mmHg at baseline to 127/81 mmHg at 12-month follow-up.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“However, RDN-induced reductions in MSNA18 and beneficial effects of RDN on conditions that are not traditionally thought to be driven by the kidney, including heart failure and arrthymia19, cannot be wholly explained by alterations in body fluid homeostasis.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“ablation of the renal nerves was also associated with a substantial decrease in muscle sympathetic nerve activity (MSNA), from 56 bursts per minute before RDN to 19 bursts per minute at 12 months after the procedure.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“The hypothesis that renal afferents mediate some of the BP effects of RDN in humans was sparked by the finding that whole-body noradrenaline spillover and MSNA were decreased in a single patient 1 year after RDN170.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [170]
Citations
Cites
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Self-citationNeural control of renal function
DiBona, G. F., & Kopp, U. C. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.1.75 · Cited by 1,212
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Schlaich, M. P., Lambert, E., Kaye, D. M., Krozowski, Z., Campbell, D. J., Lambert, G., Hastings, J., Aggarwal, A., & Esler, M. D. (2004) · Hypertension · doi:10.1161/01.hyp.0000103160.35395.9e · Cited by 514
Self-citationNoradrenaline Release and the Pathophysiology of Primary Human Hypertension
Esler, M., Jennings, G., & Lambert, G. (1989) · American Journal of Hypertension · doi:10.1093/ajh/2.3.140s · Cited by 138
Self-citation
Cited by
Items 201–300 of 763
Membrane-Targeting Approaches for Enhanced Cancer Cell Destruction with Irreversible Electroporation
Jiang, C., Qin, Z., & Bischof, J. C. (2013) · Annals of Biomedical Engineering · doi:10.1007/s10439-013-0882-7 · Cited by 39
Renal sympathetic nervous system and the effects of denervation on renal arteries
Kannan, A., Medina, R., Nagajothi, N., & Balamuthusamy, S. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i8.814 · Cited by 36
Renal denervation in multiple renal arteries
Verloop, W. L., Vink, E. E., Spiering, W., Blankestijn, P. J., Doevendans, P. A., Bots, M. L., Vonken, E.-J. P. A., & Voskuil, M. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12289 · Cited by 32
Sympathetic Renal Innervation and Resistant Hypertension
Campese, V. M., Ku, E., & Park, J. (2011) · International Journal of Hypertension · doi:10.4061/2011/814354 · Cited by 37
“describes a 59-yearold patient on seven antihypertensive medications who underwent renal sympathetic ablation of the afferent renal nerves, which resulted in a BP reduction to 127/81 mg Hg from a baseline blood pressure of 161/107 mm Hg over a twelve-month period [62].”
Renal sympathetic denervation in hypertension
Doumas, M. N., Faselis, C. J., & Papademetriou, V. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32834b620c · Cited by 35
de Beus, E., de Jager, R. L., Joles, J. A., Grassi, G. M., & Blankestijn, P. J. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000210 · Cited by 34
“[98] reports a decrease in noradrenaline spillover of 48 and 75% in the kidneys of their patient accompanied by a reduction in total body noradrenaline spillover of 42%, halving of renin activity, and a great reduction in MSNA after RDN.”
BackgroundThe Role of Central Nervous System Mechanisms in Resistant Hypertension
Hering, D., & Schlaich, M. P. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0570-0 · Cited by 35
“8 reduction of whole body NA spillover, renal NA spillover and postganglionic efferent multiunit MSNA in addition to BP improvement has also been demonstrated in patients with RH in the short-term [42, 12, 13] and longer term [14] out to 12 months post RDN.”
BackgroundSelf-citationLohmeier, T. E., & Iliescu, R. (2012) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00552.2012 · Cited by 33
Complex reinnervation pattern after unilateral renal denervation in rats
Rodionova, K., Fiedler, C., Guenther, F., Grouzmann, E., Neuhuber, W., Fischer, M. J. M., Ott, C., Linz, P. R., Freisinger, W., Heinlein, S., et al. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00227.2014 · Cited by 35
“In a separate study, renal denervation in hypertensive patients 495 was found to lower blood pressure and muscle sympathetic nerve activity (MSNA), as well as 496 whole body catecholamine spill-over (39).”
BackgroundMethodVollmann, D., Sossalla, S. T., Schroeter, M. R., & Zabel, M. (2012) · Clinical Research in Cardiology · doi:10.1007/s00392-012-0529-y · Cited by 33
“Its beneficial effects on sympathetic nerve activity [7], the renin-angiotensin-aldosterone system [8], cardiac afterload and left ventricular diastolic dysfunction [9] have also inspired recent interest in its potential impact on AF [10, 11].”
BackgroundSchlaich, M. P., Esler, M., Fink, G. D., Osborn, J. W., & Euler, D. E. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02144 · Cited by 35
Self-citationRenal Denervation Prevents Atrial Arrhythmogenic Substrate Development in CKD
Hohl, M., Selejan, S.-R., Wintrich, J., Lehnert, U., Speer, T., Schneider, C., Mauz, M., Markwirth, P., Wong, D. W. L., Boor, P., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.320104 · Cited by 33
Goldstein, D. S. (2013) · Comprehensive physiology · doi:10.1002/cphy.c130006 · Cited by 37
Role of Adjuvant Renal Sympathetic Denervation in the Treatment of Ventricular Arrhythmias
Evranos, B., Canpolat, U., Kocyigit, D., Coteli, C., Yorgun, H., & Aytemir, K. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.07.036 · Cited by 30
Removing the hype from hypertension
Shun-Shin, M. J., Howard, J. P., & Francis, D. P. (2014) · BMJ · doi:10.1136/bmj.g1937 · Cited by 30
Zannad, F. M., Stough, W. G., Mahfoud, F., Bakris, G. L., Kjeldsen, S. E., Kieval, R. S., Haller, H. G., Yared, N., Ferrari, G. M. D., Piña, I. L., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04057 · Cited by 31
“Assuming that the primary mechanism of action of programmable autonomic modulating devices is to reduce central sympathetic outflow and to improve parasympathetic activity, methods to assess the extent to which this is achieved according to the intensity of the stimulation are not well validated or practical for clini…”
BackgroundRenal denervation to treat resistant hypertension: Guarded optimism
Thomas, G., Shishehbor, M. H., Bravo, E. L., & Nally, J. V. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12040 · Cited by 32
“19 Decreased renin secretion, via circulating angiotensin II, may affect central sympathetic outflow as well.”
Santisteban, M. M., Zubcevic, J. A., Baekey, D. M., & Raizada, M. K. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0361-4 · Cited by 34
Circulating renalase, catecholamines, and vascular adhesion protein 1 in hypertensive patients
Maciorkowska, D., Zbroch, E., & Małyszko, J. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2015.08.002 · Cited by 30
Kario, K. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.4.456 · Cited by 29
Resistant Hypertension Workup and Approach to Treatment
Makris, A. P., Seferou, M., & Papadopoulos, D. P. (2010) · International Journal of Hypertension · doi:10.4061/2011/598694 · Cited by 32
Beta blockers in patients with end‐stage renal disease—Evidence‐based recommendations
Weir, M. A., & Herzog, C. A. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12691 · Cited by 31
The role of the renal afferent and efferent nerve fibers in heart failure
Booth, L. C., May, C. N., & Yao, S. T. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00270 · Cited by 31
“…nerve activity causes a reflex increase in sympathetic outflow and worsening hypertension (Katholi and Woods, 1987; Campese et al., 1995) and there is evidence that ablation of the afferent nerve fibers reduced muscle SNA (Schlaich et al., 2009) and plasma noradrenaline (Ezzahti et al., 2014).”
BackgroundScholz, E., Raake, P. W. J., Thomas, D., Vogel, B., Katus, H. A., & Blessing, E. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0749-4 · Cited by 29
“Despite these negative results on blood pressure control, RDN has been shown to effectively modulate sympathetic activity, especially in highly innervated organs, such as the heart and the kidneys [9, 20].”
BackgroundYao, Y., Fomison‐Nurse, I. C., Harrison, J. C., Walker, R. J., Davis, G., & Sammut, I. A. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00578.2013 · Cited by 31
“In several clinical trials, BRD was demonstrated to provide long-term blood pressure reduction in patients with difficult-to-control and resistant hypertension (16, 31, 38, 43, 51, 53).”
BackgroundCatheter-based renal sympathetic denervation: a targeted approach to resistant hypertension.
Gewirtz, J. R., & Bisognano, J. D. (2011) · PubMed · Cited by 28
Persu, A., Renkin, J. P., Asayama, K., O'Brien, E. T., & Staessen, J. A. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.52 · Cited by 27
Grassi, G. M., Seravalle, G., Brambilla, G., & Mancia, G. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.11.005 · Cited by 33
The role of the kidney and the sympathetic nervous system in hypertension
Thomas, P., & Dasgupta, I. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2789-4 · Cited by 36
“This technique causes significant reductions in blood pressure, which is associated with reduced whole-body and renal noradrenaline spillover, reduced muscle SNA using microneurography, improved cardiac baroreflex sensitivity and lowered left ventricular mass [140].”
MethodThe Sympathorenal Axis in Hypertension and Heart Failure
Goldsmith, S. R., Sobotka, P. A., & Bart, B. A. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.12.022 · Cited by 31
Self-citationPeters, C. D., Mathiassen, O. N., Vase, H. Ø., Bech, J. N., Christensen, K. L., Schroeder, A. P., Rickers, H., Kampmann, U., Poulsen, P. L., Langfeldt, S., et al. (2017) · Blood Pressure · doi:10.1080/08037051.2017.1368368 · Cited by 29
“A pronounced reduction in MSNA and norepinephrine spillover has been reported after RDN in a casuistic report [39] and in the study by Hering et al.”
ResultComprehensive mapping of sensory and sympathetic innervation of the developing kidney
N'Guetta, P.-E., McLarnon, S. R., Tassou, A., Geron, M., Shirvan, S., Hill, R. Z., Scherrer, G., & O’Brien, L. L. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114860 · Cited by 30
Wang, X., Zhao, Q., Deng, H., Wang, X., Guo, Z., DAI, Z., Xiao, J., Wan, P., & Huang, C. (2014) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.12429 · Cited by 26
Gao, J., Xie, Y., Yang, W., Zheng, J., & Liu, Z. (2016) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2016.07.007 · Cited by 27
Feng, Q., Lu, C., Wang, L., Song, L., Li, C., & Uppada, R. C. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0498-1 · Cited by 26
“The activities of the systemic SNS and RAS [3, 4] were shown to be decreased by RDN through interruption of the renal sympathetic efferent and afferent nerves [5].”
BackgroundInfluentialRossi, N. F., Pajewski, R., Chen, H., Littrup, P. J., & Maliszewska-Scislo, M. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00331.2015 · Cited by 25
Staico, R., Armaganijan, L., Moreira, D. A. R., de Medeiros, P. J., Melo, J., Lópes, R. D., Costa, J. R., & Abizaid, A. (2014) · EuroIntervention · doi:10.4244/eijv10i1a25 · Cited by 25
Nammas, W., Airaksinen, J. K. E., Paana, T., & Karjalainen, P. P. (2016) · Heart Rhythm · doi:10.1016/j.hrthm.2016.08.043 · Cited by 26
“In a case report, bilateral RDN reduced whole body norepinephrine spillover by 42%.(35) Pathologic long-term increase of efferent sympathetic nerve signaling operates in a number of chronic disease states characterized by sympathetic overactivity, such as hypertension, heart failure, arrhythmias, insulin resistance, a…”
BackgroundSympathetic Pathophysiology in Hypertension Origins: The Path to Renal Denervation
Esler, M., Osborn, J. W., & Schlaich, M. P. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.21715 · Cited by 30
Self-citationAllen, A. M. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.12.003 · Cited by 25
Predictors for profound blood pressure response in patients undergoing renal sympathetic denervation
Fengler, K., Rommel, K., Blazek, S., von Roeder, M., Besler, C., Hartung, P., Desch, S., Thiele, H., & Lurz, P. C. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001739 · Cited by 27
Böhm, M., Ukena, C., Ewen, S., Linz, D., Živanović, I., Hoppe, U. C., Narkiewicz, K., Ruilope, L. M., Schlaich, M. P., Negoita, M., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001085 · Cited by 25
“The SBP-lowering effect has been mainly attributed to a reduction of sympathetic activity as measured by norepinephrine spillover and microneurography for muscle sympathetic nerve activity [26,27].”
BackgroundSelf-citationY Are Males So Difficult to Understand? A Case Where “X” Does Not Mark the Spot
Sampson, A. K., Jennings, G., & Chin-Dusting, J. P. F. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.187880 · Cited by 29
Potential role of renal sympathetic denervation for the treatment of cardiac arrhythmias
Ukena, C., Mahfoud, F., Linz, D., Böhm, M., & Neuberger, H. (2013) · EuroIntervention · doi:10.4244/eijv9sra19 · Cited by 25
Renal Nerves in the Maintenance of Hypertension: A Potential Therapeutic Target
Katholi, R. E., Rocha‐Singh, K. J., Goswami, N. J., & Sobotka, P. A. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0108-4 · Cited by 28
Self-citationJancovski, N., Bassi, J. K., Carter, D. A., Choong, Y., Connelly, A. A., Nguyen, T.-P., Chen, D., Lukoshkova, E. V., Menuet, C., Head, G. A., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01474 · Cited by 25
“Elevated sympathetic activity is observed in hypertensive people and experimental models of hypertension, and approaches to reduce this, such as renal nerve denervation, are effective antihypertensive therapies.(10)”
BackgroundAbdulla, M. H., & Johns, E. J. (2017) · Acta Physiologica · doi:10.1111/apha.12856 · Cited by 24
Seravalle, G., D’Arrigo, G., Tripepi, G. L., Mallamaci, F., Brambilla, G., Mancia, G., Grassi, G. M., & Zoccali, C. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx200 · Cited by 26
“In this patient, BP progressively attained normal values over the following year while MSNA gradually declined over the same time interval [8].”
BackgroundInfluentialRethinking Resistant Hypertension
Bourque, G., & Hiremath, S. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051455 · Cited by 29
“Initial reports on the use of this technique showed effective reduction in BP, up to 20 to 30 mmHg, in patients with severe RH [33,34].”
MethodRenal Sympathetic Denervation for Treating Resistant Hypertension
Polimeni, A., Curcio, A., & Indolfi, C. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0297 · Cited by 24
Booth, L. C., Schlaich, M. P., Nishi, E. E., Yao, S. T., Xu, J., Ramchandra, R., Lambert, G. W., & May, C. N. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.440 · Cited by 23
Self-citationElectrical carotid sinus stimulation in treatment resistant arterial hypertension
Jordan, J., Heusser, K., Brinkmann, J., & Tank, J. (2012) · Autonomic Neuroscience · doi:10.1016/j.autneu.2012.10.009 · Cited by 22
Lu, J., Ling, Z., Chen, W., Du, H., Xu, Y., Fan, J., Long, Y., Chen, S., Xiao, P., Liu, Z., et al. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313506480 · Cited by 25
Volpe, M., & Tocci, G. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.47 · Cited by 22
Sata, Y., & Schlaich, M. P. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415624156 · Cited by 25
Self-citationChen, W., Chang, Y., He, L., Jian, X., Li, L., Gao, L., Yang, Y., Zeng, M., Liu, H., Zhao, A. Z., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001087 · Cited by 25
“However, the effect of renal denervation on MSNA is quite controversial [14,15].”
BackgroundJiang, Z., Zhou, X., Chen, C., Wang, Y., Ping, F., Geng, J., Zhang, G., & Shan, Q. (2018) · International Heart Journal · doi:10.1536/ihj.17-129 · Cited by 22
Shanks, J. A., de Morais, S. D. B., Gao, L., Zucker, I. H., & Wang, H. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13285 · Cited by 24
Sympathetic Signatures of Cardiovascular Disease
Osborn, J. W., & Kuroki, M. T. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.182899 · Cited by 22
Renal denervation in hypertensive patients not on blood pressure lowering drugs
de Jager, R. L., Sanders, M. F., Bots, M. L., Lobo, M. D., Ewen, S., Beeftink, M. M. A., Böhm, M., Daemen, J., Dörr, O., Hering, D., et al. (2016) · Clinical Research in Cardiology · doi:10.1007/s00392-016-0984-y · Cited by 22
“Percutaneous renal denervation (RDN) of the sympathetic nerves surrounding the renal arteries has been introduced as a therapy for (resistant) hypertension [2, 3].”
BackgroundSelf-citationWang, Y., Dinh, T. N., Nield, A., Krishna, S. M., Denton, K. M., & Golledge, J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00215 · Cited by 23
“…denervation (RDN) is used in clinical practice to lower blood pressure in treatment-resistant hypertension (Krum et al., 2009; Esler et al., 2010; Worthley et al., 2013; Bhatt et al., 2014; Papademetriou et al., 2014) by inhibiting the sympathetic outflow from the brain (Schlaich et al., 2009).”
BackgroundInfluentialTaming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation
Azzam, O., Nejad, S. H., Carnagarin, R., Nolde, J. M., Kiuchi, M. G., & Schlaich, M. P. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16247 · Cited by 22
“…dampen sympathetic nervous system activation and consequently lower BP. Early work in this space showed impressive BP lowering effects accompanied by reductions in surrogate markers of sympathetic nervous system overactivation (Hering et al., 2013; Schlaich, Sobotka, Krum, Lambert, & Esler, 2009).”
BackgroundSelf-citationLiu, S., Lekawanvijit, S., Kompa, A. R., Wang, B. H., Kelly, D. J., & Krum, H. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05632.x · Cited by 22
Self-citationFujisawa, Y., Nagai, Y., Bai, L., Nakano, D., Fukui, T., Hitomi, H., Mori, H., Masaki, T., & Nishiyama, A. (2011) · Hypertension Research · doi:10.1038/hr.2011.115 · Cited by 21
McArdle, M. J., deGoma, E. M., Cohen, D. L., Townsend, R. R., Wilensky, R. L., & Giri, J. S. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001415 · Cited by 25
“Noradrenaline spillover, in which infusions of radiolabeled noradrenaline spill over by avoiding local neuronal uptake, characterizes regional and whole-body sympathetic activity.(14) Muscle sympathetic nerve activity assesses nerve-firing rates to determine sympathetic outflow to muscle motor units.”
BackgroundRenal denervation in cardiometabolic disease: Concepts, achievements and perspectives
Grassi, G. M. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.09.004 · Cited by 21
“allow to draw a complete picture of the effects, given the evidence that not infrequently the information are anecdotic [31] or incomplete [4].”
BackgroundRenal nerves in blood pressure regulation
Johns, E. J., & Abdulla, M. H. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283641a89 · Cited by 22
“reduce sympathetic outflow in animal models of hypertension [6,7] and in humans [8,9].”
BackgroundRenal Sympathetic Denervation: A Viable Option for Treating Resistant Hypertension
Schlaich, M. P. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx033 · Cited by 21
Self-citationRenal denervation: potential impact on hypertension in kidney disease?
Blankestijn, P. J., & Ritz, E. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr190 · Cited by 21
“In one patient, MSNA, assessed in the peroneal nerve, was reduced after the procedure, providing direct support to the hypothesis that blood pressure lowering is caused by reduction of efferent sympathetic activity from the CNS to the periphery [17].”
BackgroundCentral nervous system mechanisms of salt-sensitive hypertension
Feng, Y., Pan, S., Verma, H., Zheng, H., Plata, A. A., Zubcevic, J. A., & Leenen, F. H. H. (2025) · Physiological Reviews · doi:10.1152/physrev.00035.2024 · Cited by 23
Catheter-based Radiofrequency Renal Sympathetic Denervation for Resistant Hypertension
DAMASCELLI, B., Patelli, G., Tichà, V., Rocca, F. D., Lattuada, S., Sala, C., Albertoni, A., D’Alessio, A., Funaro, A., & Scotti, L. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2013.01.491 · Cited by 20
Madhavan, M., DeSimone, C. V., Ebrille, E., Mulpuru, S. K., Mikell, S. B., Johnson, S. B., Suddendorf, S. H., Ladewig, D. J., Gilles, E. J., Danielsen, A. J., et al. (2014) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12466 · Cited by 20
The Baroreflex in Hypertension
Fernandez, G., Lee, J. A., Liu, L. C., & Gassler, J. P. (2015) · Current Hypertension Reports · doi:10.1007/s11906-014-0531-z · Cited by 26
Chen, W., Du, H., Lu, J., Ling, Z., Long, Y., Xu, Y., Xiao, P., Gyawali, L., Woo, K.-S., Yin, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep37218 · Cited by 22
Renal Sympathetic Denervation for Hypertension
Guber, K., & Kirtane, A. J. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.06.019 · Cited by 23
“In 10 patients with resistant hypertension treated with radiofrequency RDN, there was a norepinephrine spillover reduction of 48% from the left kidney and 75% from the right kidney, with a marked “wholebody” norepinephrine spillover reduction of 42%.(7)”
BackgroundRenal denervation in the antihypertensive arsenal – knowns and known unknowns
Messerli, F. H., Bavishi, C., Brguljan-Hitij, J., Burnier, M., Dobner, S., Elijovich, F., Ferdinand, K. C., Kjeldsen, S. E., Laffer, C. L., Ram, C. V. S., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003171 · Cited by 23
“RDN was shown to be effective in reducing sympathetic activity [62].”
BackgroundRenal sympathetic nerve ablation for treatment‐resistant hypertension
Krum, H., Schlaich, M. P., & Sobotka, P. A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12171 · Cited by 23
Self-citationRenal Denervation for Treatment of Cardiac Arrhythmias: State of the Art and Future Directions
Kosiuk, J., Hilbert, S., Pokushalov, E. A., Hindricks, G., Steinberg, J. S., & Bollmann, A. (2014) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12553 · Cited by 21
Expanding the indication spectrum: renal denervation in diabetes
Mahfoud, F., Ewen, S., Ukena, C., Linz, D., Sobotka, P. A., Cremers, B., & Böhm, M. (2013) · EuroIntervention · doi:10.4244/eijv9sra20 · Cited by 19
Self-citationEffects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertension
Ukena, C., Seidel, T., Rizas, K. D., Scarsi, D., Millenaar, D., Ewen, S., Bauer, A., Mahfoud, F., & Böhm, M. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01543-6 · Cited by 20
Renal Sympathetic Denervation: A Comprehensive Review
Akinseye, O. A., Ralston, W. F., Johnson, K., Ketron, L., Womack, C. R., & Ibebuogu, U. N. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100598 · Cited by 21
Neurohormonal modulation in pulmonary arterial hypertension
Peters, E. L., Bogaard, H. J., Noordegraaf, A. V., & de Man, F. S. (2021) · European Respiratory Journal · doi:10.1183/13993003.04633-2020 · Cited by 19
“For example, it was shown that inhibition of classical RAAS signalling by ACE inhibitors or AT 1 R blockers increases PNS activity [18] and reduces SNS activity [19].”
Pathogenesis of Drug-Resistant Hypertension
Townsend, R. R. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.004 · Cited by 23
Renal Denervation: A Potential New Treatment for Severe Hypertension
Huan, Y., & Cohen, D. L. (2012) · Clinical Cardiology · doi:10.1002/clc.22071 · Cited by 19
Renal Denervation and Left Ventricular Mass Regression
Bakris, G. L., & Nathan, S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.015 · Cited by 19
Recent advances in the treatment of hypertension
Hering, D., Esler, M., Krum, H., Mahfoud, F., Böhm, M., Sobotka, P. A., & Schlaich, M. P. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.71 · Cited by 20
Self-citationRenal denervation for the management of resistant hypertension
Patel, H. C., Hayward, C., Vassiliou, V. S., Patel, K., Howard, J. P., & Mario, C. D. (2015) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s65632 · Cited by 22
“In humans, peroneal nerve microneurography has been used to demonstrate reduced central nervous system sympathetic discharge after afferent (and efferent) renal denervation following nephrectomy in patients with end-stage renal failure(23) and after RSD in a patient with hypertension.(22,24)”
Pathophysiology I: the kidney and the sympathetic nervous system
de Jager, R. L., & Blankestijn, P. J. (2013) · EuroIntervention · doi:10.4244/eijv9sra8 · Cited by 22
Geng, J., Chen, C., Zhou, X., Qian, W., & Shan, Q. (2017) · International Heart Journal · doi:10.1536/ihj.16-413 · Cited by 19
Pan, T., Guo, J., Ling, L., Qian, Y., Dong, Y.-H., Yin, H.-Q., Zhu, H., & Teng, G. (2018) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2017.12.011 · Cited by 19
Is renal denervation still a treatment option in cardiovascular disease?
Hoogerwaard, A. F., & Elvan, A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.05.006 · Cited by 20
Renal sympathetic nerves – what have they got to do with cardiovascular disease?
Barrett, C. J. (2015) · Experimental Physiology · doi:10.1113/expphysiol.2014.080176 · Cited by 20
“…pressure, renal nerve ablation has been reported to lead to reductions in muscle sympathetic nerve activity and plasma noradrenaline levels (Schlaich et al. 2009; Hering et al. 2013), suggesting that elevated renal nerve activity has the potential to feedback centrally to drive increases…”
BackgroundNeuroadrenergic disarray in pseudo-resistant and resistant hypertension
Grassi, G. M., Bombelli, M., Buzzi, S., Volpe, M., & Brambilla, G. (2014) · Hypertension Research · doi:10.1038/hr.2014.25 · Cited by 18
Chen, W., Liu, H., Wang, Z., Liu, C., Fan, J., Wang, Z., Xu, Y., Zhang, B., Gyawali, L., Li, Q., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01625 · Cited by 19
“The RDN technique has been shown to reduce the wholebody noradrenaline spillover (Schlaich et al., 2009) and muscle sympathetic nerve activity (MSNA) (Hering et al.”
BackgroundMethodSimonetti, G., Spinelli, A., Gandini, R., Ros, V. D., Gaspari, E., Coco, I., Francesco, M. D., Santucci, D., Daniele, N. D., & Lauro, R. (2012) · La radiologia medica · doi:10.1007/s11547-011-0766-6 · Cited by 17
“This evidence correlates with an increased risk of hypertension, vascular remodelling, left ventricular hypertrophy, ventricular arrhythmias and sudden cardiac death [16].”
BackgroundImproved Heart Rate Dynamics in Patients Undergoing Percutaneous Renal Denervation
Himmel, F., Weil, J., Reppel, M., Mortensen, K., Franzen, K. F., Leidinger, A., Schunkert, H., & Bode, F. (2012) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00658.x · Cited by 17
“Autonomic sympathetic activation plays a key role in the pathophysiology of systemic hypertension and left ventricular hypertrophy.(1,2) As shown in the Symplicity HTN-1 and HTN-2 trials, percutaneous renal denervation (PRD) has proven to be an effective and safe method to treat patients with medically resistant hyper…”
BackgroundThe Future of Renal Denervation in Resistant Hypertension
Nathan, S., & Bakris, G. L. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0494-0 · Cited by 17
Large Artery Stiffness: A Companion to the 2015 AHA Science Statement on Arterial Stiffness
Rey-García, J., & Townsend, R. R. (2021) · Pulse · doi:10.1159/000518613 · Cited by 17
Major pathways of the reno–cardiovascular link: the sympathetic and renin–angiotensin systems
Blankestijn, P. J., London, G. M., Fliser, D., Jager, K. J., Lindholm, B., Goldsmith, D. J. A., Więcek, A., Süleymanlar, G., Agarwal, R., Ortíz, A., et al. (2011) · Kidney International Supplements · doi:10.1038/kisup.2011.3 · Cited by 20
“A substantial drop in MSNA was reported in one patient.(18) More recently, this antihypertensive effect was confirmed in a randomized trial.”
BackgroundIerna, S., Biondi‐Zoccai, G., Bachis, C., Occhipinti, M., Vito, L. D., Ricciardi, A., Pappone, C., & Prati, F. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.056 · Cited by 17
“The safety profile of this novel technique appears satisfactory [2–6], but there is still limited insight on how such denervation works.”
Background
Metadata
- Authors
- Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., & Esler, M. D.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- University of Oklahoma Health Sciences Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-08-27
- Volume
- 361
- Issue
- 9
- Pages
- 932-934
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1994487234
- Cited by
- 772
- References
- 5
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 19 · 2023: 25 · 2022: 22 · 2021: 19 · 2020: 19 · 2019: 27 · 2018: 31 · 2017: 42 · 2016: 42 · 2015: 52 · 2014: 115 · 2013: 136 · 2012: 95
- FWCI
- 42.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- uncontrolled hypertension, bevacizumab, hereditary hemorrhagic telangiectasia, pulmonary arteriovenous malformation, intermittent dosing, long-term drug safety, iron requirements
- MeSH terms
- Humans, Hypertension, Kidney, Male, Middle Aged, Norepinephrine, Renal Artery, Sympathectomy, Catheter Ablation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.